Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC.

Carcinogenesis. 2008 May;29(5):905-12. doi: 10.1093/carcin/bgn049. Epub 2008 Feb 24.

2.

The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation.

You HJ, Bruinsma MW, How T, Ostrander JH, Blobe GC.

Carcinogenesis. 2007 Dec;28(12):2491-500. Epub 2007 Sep 3.

PMID:
17768179
3.

The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.

You HJ, How T, Blobe GC.

Carcinogenesis. 2009 Aug;30(8):1281-7. doi: 10.1093/carcin/bgp071. Epub 2009 Mar 26.

5.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.

6.

The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Lee JD, Hempel N, Lee NY, Blobe GC.

Carcinogenesis. 2010 Feb;31(2):175-83. doi: 10.1093/carcin/bgp271. Epub 2009 Dec 2.

7.

TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.

Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC.

Carcinogenesis. 2008 Mar;29(3):528-35. doi: 10.1093/carcin/bgm289. Epub 2008 Jan 3.

PMID:
18174241
8.

The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.

Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC.

Cancer Res. 2007 Feb 1;67(3):1090-8.

9.

The type III TGF-beta receptor suppresses breast cancer progression.

Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC.

J Clin Invest. 2007 Jan;117(1):206-17. Epub 2006 Dec 7.

10.

Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC.

Neoplasia. 2011 Aug;13(8):758-70.

11.

Overexpression of transforming growth factor type III receptor restores TGF-β1 sensitivity in human tongue squamous cell carcinoma cells.

Li D, Xu D, Lu Z, Dong X, Wang X.

Biosci Rep. 2015 Jul 23;35(4). pii: e00243. doi: 10.1042/BSR20150141.

12.

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA.

Oncogene. 2010 May 20;29(20):2905-15. doi: 10.1038/onc.2010.64. Epub 2010 Mar 8.

13.

Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.

Criswell TL, Dumont N, Barnett JV, Arteaga CL.

Cancer Res. 2008 Sep 15;68(18):7304-12. doi: 10.1158/0008-5472.CAN-07-6777.

14.

Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression.

Zhang S, Sun WY, Wu JJ, Gu YJ, Wei W.

Oncol Rep. 2016 Apr;35(4):2373-81. doi: 10.3892/or.2016.4615. Epub 2016 Feb 8.

PMID:
26882862
15.
16.

Transforming growth factor-β1 up-regulates connexin43 expression in human granulosa cells.

Chen YC, Chang HM, Cheng JC, Tsai HD, Wu CH, Leung PC.

Hum Reprod. 2015 Sep;30(9):2190-201. doi: 10.1093/humrep/dev175. Epub 2015 Jul 22.

19.

Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta.

Ungefroren H, Groth S, Ruhnke M, Kalthoff H, Fändrich F.

J Biol Chem. 2005 Jan 28;280(4):2644-52. Epub 2004 Nov 16.

20.

MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.

Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, Trepel JB, Kim SJ.

Cancer Res. 2001 Feb 1;61(3):931-4.

Supplemental Content

Support Center